stockportfolio.pro logostockportfolio.pro
Stocks Screener Start 7-day free trial
Stocks / LGND / Free Cash Flow

Ligand Pharmaceuticals Incorporated Free Cash Flow 2009–2025

Ligand Pharmaceuticals Incorporated (LGND) annual free cash flow by fiscal year, computed from SEC filings.

Fiscal yearFree Cash FlowChange (YoY)
FY 2025$48.91M-48.6%
FY 2024$95.23M+106.8%
FY 2023$46.06M-61.6%
FY 2022$119.93M+71.2%
FY 2021$70.04M+39.7%
FY 2020$50.13M+257.2%
FY 2019$-31.89M-116.5%
FY 2018$193.17M+123.5%
FY 2017$86.41M+46.8%
FY 2016$58.88M+41.4%
FY 2015$41.63M+102.5%
FY 2014$20.56M+1.2%
FY 2013$20.31M+4780.4%
FY 2012$-434,000+65.3%
FY 2011$-1.25M+95.4%
FY 2010$-27.14M+20.9%
FY 2009$-34.32M

Source: Ligand Pharmaceuticals Incorporated SEC filings — cash flow statement (10-K). Refreshed nightly.

See the full picture for Ligand Pharmaceuticals Incorporated

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

Ligand Pharmaceuticals Incorporated — frequently asked questions

What is Ligand Pharmaceuticals Incorporated's free cash flow?

Ligand Pharmaceuticals Incorporated (LGND) reported free cash flow of $48.91M for fiscal year 2025, per its SEC filings.

Where does this data come from?

Figures are computed from Ligand Pharmaceuticals Incorporated's official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.

More LGND financial history

Full LGND fundamentals page → · All 1,500+ companies →